We treated 19 patients who had hormone-resistant adenocarcinoma of the prostate (stage D-2) with 5-FU, doxorubicin, and mitomycin (FAM'). All patients had extremely poor prognostic factors. Of the 16 patients evaluable for response, 44% had stabilization of disease and 56% had progressive disease. The median survival time for the stable disease group was 48 weeks, whereas that for the nonresponders was 26 weeks. The difference in survival time was statistically significant (P less than 0.002). The FAM' regimen was well-tolerated with minimal nausea, no vomiting, and moderate hematologic toxicity.